
How a Virtual Behavioral Health Program Is Reaching Patients With Cancer Who Need It Most
Key Takeaways
- Referrals embedded in routine community oncology operations produced meaningful engagement, with 1400 referred, 850 consenting/scheduling intake, and 631 starting longitudinal virtual behavioral health care.
- Enrollment captured a high-proportion underserved population, including 43.5% BIPOC overall, 36.5% Black among initiators, and 18.7% Medicaid-insured patients.
Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.
A cancer diagnosis takes a psychological toll that's well documented but rarely well addressed. Most patients who need behavioral health support never receive it, and the patients most likely to be left out are often the ones already facing the steepest climb. Researchers in a new study presented during the
"I think that the unmet needs that we're primarily trying to address are the whole-person care and the psychosocial support for patients living with cancer,” Lavin said. The scale of the problem, in his view, is the real starting point. "We know that 60% to 80% of patients who have a serious cancer diagnosis have some level of distress, and we know that typically less than 10% of patients access this type of care."
That gap isn't evenly distributed, he added. "Our study that we presented at ASCO showed that the Medicaid population specifically presents with higher levels of depression and anxiety and lower levels of quality of life," Lavin said. The logic behind the intervention follows directly from that finding. "By integrating this behavioral health directly into the oncology workflow, into the oncology practices, these patients—all patients—are more likely to access care, but especially the underserved populations are more likely to enroll." The reach achieved bears that out, he noted, with Black, Indigenous, and people of color (BIPOC) patients making up 43.5% of the study population.
Inside the Study Design
The researchers tracked patients across community oncology practices who were referred into a virtual collaborative behavioral health model run by Cerula Care, of which Lavin is the cofounder and chief medical officer. "We looked at patients in a community oncology practice setting who initiated care for their oncologic conditions, and a referral was made for the collaborative behavioral care model,” Balanchivadze explained. "Cerula Care received the referrals, enrolled the patients, and measured patients in different key factors…[including] depression, anxiety, and quality of life."
Beyond symptom tracking, the researchers also looked at downstream behavior. "In addition to that, [we] measured patient satisfaction and adherence to visits, oncology care visits, and adherence to medications or prescribed treatments. This was measured at baseline and then measured longitudinally,” Balanchivadze said.
In practice, the numbers behind that design were substantial: Oncology providers referred 1400 patients into the program, 850 consented and scheduled an intake, and 631 ultimately completed intake and began behavioral health care.
What the Data Showed
The headline finding, for Balanchivadze, was reach. Among the 631 patients who initiated care, 36.5% identified as Black, and the Medicaid population landed at 18.7%—both notably higher than these groups' typical representation in behavioral health services.
Symptom severity at intake told its own story. "We looked at the severity of symptoms upon presentation, both for BIPOC and for the Medicaid population. [It] was slightly higher for BIPOC, although not [statistically] significant,[whereas] for the Medicaid population, there were statistically significant higher levels of depression, as measured by the PHQ-9 [Patient Health Questionnaire-9]; anxiety as measured by the GAD-7 [Generalized Anxiety Disorder-7 questionnaire]; and lower levels of quality of life [as] measured by the FACT-G7 [Functional Assessment of Cancer Therapy-G7]," Lavin said.
What stood out most, though, was what happened after patients entered care. "Those patients, even though they had higher distress, actually improved equally—if not directionally greater improvement—in those reductions in depression, anxiety scores, and improvement in quality of life scores," Lavin said. In other words, patients who started out worse off didn't fall further behind. If anything, the data trended the other way. Patient-reported satisfaction was high as well, with a Net Promoter Score of 88, and a majority of patients reported improved adherence both to oncology visits and to nonchemotherapy medications.
Why Community Oncology Is the Right Setting for This Work
For Balanchivadze, a practicing community oncologist, the choice to study this model specifically in the community setting, rather than at a large academic center, wasn't incidental. "I think the significance is huge," she said, "because at the community level, there are so many patient-related stressors...even physical distance to the oncologist's office. I see a lot of patients who live in remote areas, where even driving to the appointment to see me is a problem." Layering additional services on top of that baseline difficulty compounds the challenge. "If you layer on other services, such as behavioral health or referral to different specialists, it really becomes a challenge for the patients," she said.
Community practices also tend to serve a broader cross-section of patients than academic centers do, Balanchivadze noted, which has its own implications for access and trust. "In the community, you also see a variety of a larger basket of different patients at different educational levels and different socioeconomic statuses, while at larger academic centers, one may see patients who are higher socioeconomic status, perhaps [allowing] them to seek care at tertiary centers," she said.
In the community setting, that range is wider. "We get patients [who] enter care at different levels of education, income levels, and various disparities,” Balanchivadze said. Those differences, she noted, can shape something as fundamental as whether a patient sticks with treatment. "That can be a contributor to adherence to the care that they receive. Trust is important as well. When [a patient] goes to a large academic center, there might be a different level of trust [in] the services provided there compared with smaller community settings,” she added.
Lavin framed the program's value in the community setting in similarly direct terms. "It's transformational to be able to bring this access to the community oncology setting," he said, noting that many community practices simply don't have dedicated psychosocial oncology resources on hand. "A lot of community oncology groups don't have as many of the psychosocial oncology support resources." He’s careful to credit the existing infrastructure that exists alongside the new model. "We work very closely with the [practice's] social work team. They do an amazing job of caring for the patients they're able to see," he said But the broader goal, he added, is to shift the posture of care from reactive to proactive: "Through this model, [we're] trying to expand access, both to the underserved population and also across the entire population, and [help] patients... be much more proactive in preventing distress, rather than reactive and waiting until distress occurs, and then we [are] dealing with a crisis."
Open Questions Going Forward
Asked what remains unanswered, Balanchivadze returns to a concern central to her day-to-day practice: medication and visit adherence. "As an oncologist, adherence is huge," she said. "I think of integrating behavioral health and proactively screening patients for adherence, and then seeing how it affects adherence to oral oncolytics, chemotherapy, or oncology visits. Because we know adherence translates into better outcomes."
The second concerns clinical trial participation. "Improving mental health resources and access to mental health, integrating into oncology care—how is that going to affect trial enrollment and participation in clinical trials?” Balanchivadze asked.



































